Coverage and Prior Authorization Policies for Semaglutide and Tirzepatide in Medicare Part D Plans

Key Points

• Prior authorization for semaglutide and tirzepatide is common in Medicare Part D plans, impacting patient access.
• The study highlights disparities in coverage trends for glucagon-like peptide-1 receptor agonists among beneficiaries.
• Analysis indicates a significant variation in prior authorization requirements, which may complicate treatment options.
• Medicare Part D policies for these medications reveal important implications for managing chronic diseases.